Quick Answer
Autolus Therapeutics plc reported Diluted EPS of $1.08 per share (loss) for fiscal year 2025.
Autolus Therapeutics plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.08 | -25.6% |
| 2024 | -$0.86 | +28.3% |
| 2023 | -$1.20 | +23.6% |
| 2022 | -$1.57 | +20.3% |
| 2021 | -$1.97 | +28.6% |
| 2020 | -$2.76 | +4.2% |
| 2019 | -$2.88 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | +3.2% | -66.7% |
| June 30, 2025 | -$0.18 | +18.2% | +30.8% |
| March 31, 2025 | -$0.26 | -8.3% | +16.1% |
| September 30, 2024 | -$0.31 | -19.2% | -40.9% |
| June 30, 2024 | -$0.22 | +15.4% | +8.3% |
| March 31, 2024 | -$0.24 | -4.3% | +7.7% |
| September 30, 2023 | -$0.26 | +44.7% | +0.0% |
| June 30, 2023 | -$0.26 | — | -13.0% |
- Autolus Therapeutics plc showed a decrease of -25.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Autolus Therapeutics plc’s diluted eps has grown by 62.5% (from $2.88 per share (loss) to $1.08 per share (loss)).
- The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: